Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951395 | 1.00 | CTSK (0.43) | CTSKCTSLCTSBCTSSCTSH | |
| SCHEMBL28951260 | 0.91 | CTSK (0.46) | CTSKCTSLCTSBCTSSMETAP2 | |
| SCHEMBL25523517 | 0.91 | CTSK (0.46) | CTSKCTSLCTSBCTSSMETAP2 | |
| SCHEMBL28951216 | 0.89 | CTSK (0.46) | CTSKCTSLCTSBCTSSSMN1; SMN2 | |
| SCHEMBL25524876 | 0.89 | CTSK (0.46) | CTSKCTSLCTSBCTSSSMN1; SMN2 | |
| SCHEMBL30174766 | 0.89 | CTSK (0.46) | CTSKCTSLCTSBCTSSSMN1; SMN2 | |
| SCHEMBL28951370 | 0.89 | CTSK (0.46) | CTSKCTSLCTSBCTSSSMN1; SMN2 | |
| SCHEMBL28951062 | 0.89 | GRN (0.47) | CTSKCTSLCTSBCTSS | |
| SCHEMBL25524071 | 0.89 | GRN (0.47) | CTSKCTSLCTSBCTSS | |
| SCHEMBL6987278 | 0.84 | CNR2 (0.39) | CTSKCTSLCTSBCTSSEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | CTSK 2355/4885CTSL 1031/4885CTSB 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.